Collagen Market Size, Share | CAGR of 9.3%

Report Overview

The Global Collagen Market size is expected to be worth around USD 19.0 Billion by 2035, from USD 7.8 Billion in 2025, growing at a CAGR of 9.3% during the forecast period from 2026 to 2035. In 2025, Asia-Pacific held a dominant market position, capturing more than a 41.23% share, holding USD 3.2 Billion revenue.

Collagen is a naturally occurring structural protein that plays an important role in maintaining the strength, elasticity, and structure of skin, bones, muscles, tendons, and connective tissues. It is widely used across the food and beverage, pharmaceutical, nutraceutical, cosmetics, healthcare, and biomedical industries. Commercial collagen is primarily obtained from bovine hides, porcine skin, poultry tissues, and marine sources such as fish skin, scales, and bones. Depending on its processing method, collagen is supplied in different forms, including hydrolyzed collagen peptides, gelatin, and native collagen.

The collagen industry operates through an integrated supply chain involving animal by-product collection, raw material processing, extraction, purification, hydrolysis, drying, and final ingredient formulation. Manufacturers are increasingly focusing on improving extraction efficiency, product purity, solubility, and bioavailability to meet the requirements of different end-use industries. According to the Food and Agriculture Organization (FAO), global fisheries and aquaculture production reached 223.2 million tonnes in 2022, comprising 185.4 million tonnes of aquatic animals and 37.8 million tonnes of algae.

The industrial scenario is increasingly influenced by investments in production capacity, specialized collagen ingredients, and technological improvements. Major manufacturers are strengthening their global operations to serve food, pharmaceutical, and health and nutrition customers. For instance, GELITA reports having more than 2,900 employees and over 20 production sites worldwide, reflecting the scale of established collagen protein manufacturing operations. Similarly, Rousselot, part of Darling Ingredients, operates 16 production facilities across eight countries and four continents.

Technological advancements represent another important factor influencing industrial development. Manufacturers are investing in enzymatic hydrolysis, advanced filtration, purification, and molecular-weight control to improve collagen quality and product consistency. These technologies help manufacturers develop ingredients with specific functional characteristics for different applications. Marine collagen extraction also provides opportunities to utilize fish-processing residues, including skin, scales, and bones.

According to the FAO, global aquaculture production of aquatic animals reached 94.4 million tonnes in 2022, exceeding capture fisheries production of approximately 91 million tonnes. This development highlights the growing availability of aquaculture-derived raw materials for downstream processing industries.

Government regulations and product-quality requirements also influence the collagen manufacturing landscape. In the United States, the Food and Drug Administration (FDA) requires dietary supplement manufacturers to comply with 21 CFR Part 111, which establishes current good manufacturing practice requirements covering manufacturing, packaging, labeling, quality control, and recordkeeping.

In Europe, Regulation (EC) No. 1069/2009 establishes requirements for animal by-products, including safe sourcing, processing, traceability, and appropriate end uses. The European Commission reports that more than 20 million tonnes of animal by-products arise annually within the European Union. These materials create opportunities for collagen and gelatin manufacturers to improve raw material utilization while maintaining appropriate safety standards.

The proposed combination represented approximately USD 1.5 billion in annual revenue, with around 200,000 metric tonnes of annual production capacity across 22 facilities. Such industrial consolidation demonstrates the importance of manufacturing scale, technological capabilities, and global distribution networks in the collagen industry. Overall, continued product innovation, improved raw material recovery, expanding nutraceutical applications, and specialized biomedical research are expected to support the long-term development of the global collagen industry. Source: Darling Ingredients, December 2025.

Key Takeaways

Collagen Market size is expected to be worth around USD 19.0 Billion by 2035, from USD 7.8 Billion in 2025, growing at a CAGR of 9.3%.
Gelatin held a dominant market position, capturing more than a 62.23% share of the collagen market.
Bovine held a dominant market position, capturing more than a 38.60% share of the collagen market.
Food & Beverages held a dominant market position, capturing more than a 53.45% share of the collagen market.
Distributors held a dominant market position, capturing more than a 67.56% share of the collagen market.
Asia-Pacific held the leading position in the global collagen market in 2025, accounting for 41.23% of the market, valued at USD 3.2 billion.

By Product Analysis

Gelatin dominates the collagen market due to its wide applications in food processing, pharmaceuticals, and functional ingredients.

In 2025, “Gelatin” held a dominant market position, capturing more than a 62.23% share of the collagen market. Its leading position is supported by its extensive use as a gelling, stabilizing, thickening, and binding ingredient across food and pharmaceutical applications. Gelatin is widely used in confectionery, dairy products, desserts, nutritional products, and pharmaceutical capsules. Its ability to improve product texture, stability, and consistency makes it an important ingredient for manufacturers.

According to the European Commission, more than 20 million tonnes of animal by-products are generated annually across the European Union, creating opportunities for the recovery and processing of animal-derived raw materials used in gelatin and collagen production. In 2025, demand for gelatin continued to benefit from its established industrial applications, processing flexibility, and availability of bovine and porcine raw materials. Pharmaceutical applications, particularly capsule manufacturing, also support its continued importance.

Hydrolyzed Collagen is gaining attention because of its suitability for dietary supplements, functional foods, and personal care products. It is produced through enzymatic or chemical breakdown of collagen proteins into smaller peptides, making it easier to incorporate into powders, capsules, gummies, and ready-to-drink beverages. Its good solubility and formulation flexibility support its adoption among nutraceutical and food ingredient manufacturers. In 2025, growing consumer interest in skin health, joint support, healthy ageing, and protein-based nutrition supported the development of hydrolyzed collagen products.

The European Commission’s Regulation (EU) No. 2016/355 establishes specific hygiene and processing requirements for gelatin and collagen intended for human consumption, supporting product safety and manufacturing quality. Furthermore, the availability of animal-derived raw materials and improvements in enzymatic processing provide opportunities for manufacturers to develop specialized collagen peptides for different applications.

By Source Analysis

Bovine collagen dominates the market due to its wide raw material availability and established use in food, pharmaceutical, and nutraceutical applications.

In 2025, “Bovine” held a dominant market position, capturing more than a 38.60% share of the collagen market. Its leading position is supported by the availability of collagen-rich materials such as cattle hides, bones, and connective tissues. Bovine collagen is widely used in dietary supplements, protein powders, functional beverages, cosmetics, and medical applications. Its established processing methods and suitability for producing gelatin and hydrolyzed collagen peptides make it an important raw material for manufacturers.

According to the United States Department of Agriculture (USDA), commercial cattle slaughter in the United States reached 29.8 million head in 2025, while beef production totaled 26.1 billion pounds. This large cattle-processing industry provides an established supply chain for bovine-derived raw materials. The availability of hides and bones from meat-processing operations further supports collagen extraction and commercial production.

Porcine collagen is obtained mainly from pig skin, bones, and connective tissues and is widely used in gelatin production, pharmaceutical formulations, and food ingredients. Its established extraction and processing methods make it a commercially important source for collagen manufacturers. In 2025, demand for porcine collagen was supported by its suitability for producing gelatin used in confectionery, desserts, processed foods, and pharmaceutical capsules.

The availability of raw materials from the pork-processing industry also supports its industrial applications. According to the USDA, commercial hog slaughter in the United States reached approximately 128.2 million head in 2025, while pork production totaled 27.6 billion pounds. This large-scale processing industry provides a significant raw material base for porcine collagen and gelatin manufacturers. Continued demand from food and pharmaceutical industries supports the segment’s industrial relevance.

By Application Analysis

Food & Beverages dominates the collagen market due to its extensive use in functional foods, confectionery, dairy products, and nutritional beverages.

In 2025, “Food & Beverages” held a dominant market position, capturing more than a 53.45% share of the collagen market. The segment’s leading position is supported by the growing use of collagen as a functional protein ingredient in food formulations. Gelatin and hydrolyzed collagen are widely incorporated into confectionery, desserts, protein drinks, nutritional bars, and dairy-based products to improve texture, stability, and nutritional value. Food manufacturers also prefer collagen because of its versatility and compatibility with different product formulations.

According to the United States Department of Agriculture (USDA), food and beverage manufacturing establishments accounted for 16.8% of total U.S. manufacturing sales in 2021 and employed approximately 1.7 million workers. This established manufacturing base provides an important industrial channel for collagen-based ingredients. In 2025, demand was further supported by the development of protein-enriched foods, functional beverages, and convenient nutritional products.

Healthcare is an important application area for collagen because of its natural compatibility with biological tissues and its ability to support wound management and tissue repair. Collagen is increasingly used in wound dressings, surgical materials, tissue-engineering products, and regenerative medicine. Its applications in medical devices are also creating opportunities for manufacturers to develop specialized, high-purity collagen materials.

In 2026, the United States Centers for Medicare & Medicaid Services (CMS) established the A2050 HCPCS Level II code for fibrillar collagen wound dressings, recognizing a specific category of collagen-based wound-care products. These dressings are used for managing different types of wounds, including surgical wounds, pressure ulcers, and burns. This development highlights the growing role of collagen in specialized healthcare products. Increasing interest in advanced wound management, biomaterials, and tissue-repair technologies is expected to create further opportunities for collagen manufacturers.

By Disribution Channel Analysis

Distributors dominate the collagen market due to their extensive supply networks and ability to connect manufacturers with multiple end-use industries.

In 2025, “Distributors” held a dominant market position, capturing more than a 67.56% share of the collagen market. Their leading position is supported by their role in supplying collagen ingredients to food and beverage manufacturers, pharmaceutical companies, nutraceutical producers, and cosmetics businesses. Distributors help manufacturers reach a wider customer base by managing bulk procurement, inventory, storage, and product delivery.

They also provide technical support, product documentation, and quality-related information to industrial buyers. Their established relationships with ingredient manufacturers and end-use companies make them an important part of the collagen supply chain. In addition, distributors help smaller manufacturers access different collagen grades, including gelatin, hydrolyzed collagen, and specialized collagen ingredients, without maintaining direct sourcing relationships with multiple producers.

B2B is an important distribution channel in the collagen market because it enables manufacturers to supply large quantities of collagen ingredients directly to food processors, pharmaceutical companies, nutraceutical brands, and cosmetics manufacturers. This channel supports long-term supply agreements, customized ingredient requirements, consistent product quality, and competitive bulk pricing. In 2025, demand through B2B channels was supported by the need for reliable sourcing of gelatin, bovine collagen, porcine collagen, and hydrolyzed collagen for commercial production.

According to the U.S. Census Bureau’s 2022 Economic Census, the United States recorded 274,236 wholesaler distributor and jobber establishments, generating approximately USD 6.72 trillion in sales. This demonstrates the scale of the wholesale distribution infrastructure supporting business-to-business transactions. The established wholesale network provides opportunities for collagen suppliers to expand industrial customer relationships and strengthen bulk ingredient distribution. Source: U.S. Census Bureau – Wholesale Trade Statistics.

Key Market Segments

By Product

Gelatin
Hydrolyzed Collagen
Native Collagen
Synthetic Collagen
Other Product

By Source

Bovine
Porcine
Poultry
Marine
Other Source

By Application

Food & Beverages
Healthcare
Cosmetics
Other Application

By Disribution Channel

B2B
Distributors

Driver Analysis

Beauty-Supplement Formulation Demand — +0.6 Percentage Points

Beauty-positioned supplements create collagen-ingredient demand because manufacturers already formulate daily powders, drinks and capsules around recognizable branded peptides, but consumer positioning must be distinguished from proven clinical benefit. GELITA currently markets a preparation-specific 2.5 g daily formulation for beauty applications, establishing an existing commercial route to market rather than evidence that all collagen products have equivalent effects. Importantly, a 2025 systematic review of 23 randomized trials involving 1,474 participants found favorable pooled skin outcomes overall, but no significant benefit in the high-quality or non-pharmaceutical-funded subgroups, leading the authors to question support for skin-ageing claims.

The commercial driver is therefore manufacturers’ continued ingredient adoption, not an analyst endorsement that collagen prevents or treats skin ageing. In a constructed customer portfolio of 1 million users purchasing 180 daily servings annually at 2.5 g per serving, collagen demand is 450 tonnes; at an assumed USD 15/kg ingredient realization, annual supplier revenue is USD 6.75 million. Increasing active users by 10% adds 45 tonnes and USD 675,000, provided serving frequency and dose remain unchanged.

The +0.6-point sensitivity assumes 25% of terminal counterfactual revenue is beauty-sensitive and achieves approximately 11.6% cumulative commercial outperformance, adding 2.9% market-wide terminal revenue. Suppliers increasingly compete through sensory performance, preparation-specific documentation and customer formulation support; repeat purchasing, lawful claims and scrutiny of evidence remain material downside risks, so retail beauty spending is not counted directly as collagen-market revenue.

Drivers Impact Analysis

Driver	(~) % Impact on CAGR Forecast	Geographic Relevance	Impact Timeline
Beauty-supplement formulation demand	+0.6 pp	US, EU, Japan, South Korea	Medium term (2–4 years)
Joint-health product adoption	+0.6 pp	US, EU, Japan, China	Long term (≥ 4 years)
Food and beverage incorporation	+0.6 pp	US, EU, China, Brazil	Medium term (2–4 years)
Medical-matrix procurement	+0.5 pp	US, EU, Japan	Long term (≥ 4 years)
Animal-nutrition portfolio expansion	+0.3 pp	US, EU, Japan	Medium term (2–4 years)
Source-qualified product portfolios	+0.4 pp	EU, US, Japan, Gulf states	Medium term (2–4 years)

Restraint Analysis

Clinical-Evidence Uncertainty — −0.5 Percentage Points

Uncertainty over preparation-specific efficacy limits premium pricing, customer retention and manufacturers’ willingness to commit to differentiated collagen ingredients, particularly in beauty applications. A 2025 systematic review included 23 randomized trials involving 1,474 participants: pooled results favored collagen for selected skin outcomes, but the high-quality and non-pharmaceutical-funded subgroups did not show significant benefits, leading the authors to question the evidence supporting skin-ageing use. That finding does not establish that every preparation is ineffective, nor does it invalidate all joint-health evidence; it weakens the assumption that a general collagen label supports a universal benefit.

In a constructed ingredient portfolio, 500 tonnes annually sold at USD 15/kg generates USD 7.5 million of revenue. If evidence scrutiny reduces purchasing volume by 10%, revenue falls USD 750,000 at constant price; separately, losing a USD 2/kg evidence-based premium on the remaining 450 tonnes removes another USD 900,000, producing USD 1.65 million of total exposure without double counting volume already lost. At an assumed USD 10/kg variable production cost, contribution falls from USD 2.5 million to USD 1.35 million before fixed expenditure.

The −0.5-point sensitivity assumes 25% of terminal counterfactual revenue is evidence-sensitive and experiences a 9.2% realization shortfall, producing approximately 2.3% market-wide terminal erosion. Suppliers must therefore fund relevant studies and disclose preparation, dose and endpoints; this restraint concerns commercial confidence, distinct from the legal ability to advertise a claim.

Restraint Impact Analysis

Restraint	(~) % Impact on CAGR Forecast	Geographic Relevance	Impact Timeline
Clinical-evidence uncertainty	−0.5 pp	US, EU, UK, Japan, South Korea	Long term (≥ 4 years)
Claim-related commercialization limits	−0.4 pp	EU; US supplement channels	Long term (≥ 4 years)
Qualified feedstock cost pressure	−0.4 pp	US, EU, Brazil, China	Medium term (2–4 years)
Dose-driven formulation costs	−0.4 pp	US, EU, China, Japan	Medium term (2–4 years)
Source and allergen exclusions	−0.3 pp	US, EU, India, Gulf states	Long term (≥ 4 years)
Medical-grade qualification barriers	−0.4 pp	US, EU, Japan	Long term (≥ 4 years)

Opportunity Analysis

Preparation-Specific Evidence Platforms — +0.5 Percentage Points

The white space is to develop independently scrutinized, preparation-specific evidence that supports additional customer applications and defensible premiums, rather than simply attach a branded claim to existing beauty or joint-health demand. This investment must address a material evidence gap: a 2025 skin-ageing meta-analysis included 23 randomized trials and 1,474 participants, but found no significant benefit in high-quality or non-pharmaceutical-funded subgroups, despite favorable overall pooled results. Supplier documentation also distinguishes peptide compositions and manufacturing conditions, reinforcing that results from one preparation should not automatically substantiate another.

In a constructed program, three candidate preparations each require USD 1.5 million of analytical, safety and human-study expenditure, creating USD 4.5 million of initial investment. If two achieve commercially relevant results and each reaches 750 tonnes annually with a USD 2/kg ingredient premium, annual premium revenue is USD 3 million; subtracting USD 600,000 of incremental production, quality and continuing evidence costs leaves USD 2.4 million before selling expense and overhead.

Simple recovery of initial research expenditure is approximately 1.9 years after reaching that volume—not from study initiation—and unsuccessful candidates remain part of the investment cost. The +0.5-point sensitivity requires approximately 2.4% incremental terminal market revenue from genuinely new customers and sustained premiums, net of ordinary branded-peptide growth already forecast. Clinical success does not guarantee a legally usable claim: authorization and wording remain jurisdiction-specific, and neither disease-treatment claims nor universal collagen efficacy is assumed.

Opportunity Impact Analysis

Opportunity	(~) % Potential CAGR	Geographic Relevance	Execution Window
Preparation-specific evidence platforms	+0.5 pp	US, EU, Japan, South Korea	Long term (≥ 4 years)
Co-located coproduct refining	+0.5 pp	Brazil, US, EU, Vietnam	Medium term (2–4 years)
Application-engineered collagen grades	+0.4 pp	US, EU, China, Japan	Medium term (2–4 years)
Native-collagen research materials	+0.4 pp	US, EU, Japan, South Korea	Long term (≥ 4 years)
Regional contract-finishing hubs	+0.3 pp	India, Indonesia, Brazil	Medium term (2–4 years)
Capability-led acquisition platforms	+0.3 pp	US, Germany, France, Singapore	Short term (≤ 2 years)

Challenges Analysis

Hydrolysis Process Reproducibility — −0.4 Percentage Points

The manufacturing challenge is reproducing a specified peptide distribution and functional profile as raw-material characteristics, enzymes, residence time and process conditions change—not simply securing enough collagen-rich input. Published technical literature explains that enzyme selection and reaction time influence peptide sizes and sequences, while chemical hydrolysis can be harder to control; supplier materials likewise distinguish collagen peptides by composition and processing characteristics. This supports process sensitivity without establishing a universal commercial yield benchmark or proving that one molecular-weight range is clinically superior.

In a constructed plant processing 10,000 tonnes of wet input annually, a 10% saleable-product yield produces 1,000 tonnes; a decline to 9.5% reduces output by fifty tonnes, or 5%. At USD 14/kg realization, that is USD 700,000 of output-value exposure before replacement supply or reprocessing. If annual fixed conversion cost is USD 2 million, fixed cost per kilogram rises from USD 2.00 to approximately USD 2.11, while recovering output may require additional enzyme, processing time or input.

The −0.4-point sensitivity assumes 25% of terminal opportunity-enabled revenue is process-sensitive and experiences a 7.6% realization shortfall, producing approximately 1.9% aggregate terminal friction through inconsistent delivery and delayed customer conversion. Mitigation requires defined operating windows, enzyme-activity verification, in-process sampling and change control; this category concerns repeatable compliant output, whereas feedstock-price inflation and rejected incoming materials remain outside the calculation.

Challenges Impact Analysis

Challenge	(~) % CAGR Friction Drag	Geographic Relevance	Mitigation Horizon
Hydrolysis Process Reproducibility	−0.4 pp	Brazil, US, EU, China	Long term (≥ 4 years)
Cross-Laboratory Specification Alignment	−0.3 pp	US, EU, Japan, China	Medium term (2–4 years)
Source-Traceability Data Integration	−0.3 pp	Brazil–EU, Asia–US, Asia–EU	Medium term (2–4 years)
Finished-Matrix Performance Consistency	−0.3 pp	US, EU, China, Japan	Medium term (2–4 years)
Transit and Inventory Synchronization	−0.3 pp	Asia–EU, Brazil–EU, Asia–US	Medium term (2–4 years)
Specialist Technical Workforce Development	−0.2 pp	US, Germany, France, China	Long term (≥ 4 years)

Geopolitical Impact Analysis

Geopolitical Impact of Ongoing Wars on the Collagen Market

The ongoing Middle East conflict and Russia-Ukraine war are creating indirect pressure on the global collagen market through higher energy costs, shipping delays, and raw material transportation challenges. Collagen manufacturers depend on a steady supply of bovine hides, porcine skin, fish-processing by-products, chemicals, and processing materials. Disruptions across the Strait of Hormuz, Red Sea, and Black Sea are increasing freight costs and making international deliveries less predictable.

According to the Central Bank of Ireland’s 2026 report, global oil supply declined by approximately 10 million barrels per day in March 2026, while Brent crude prices increased from USD 69 per barrel in February to USD 104 per barrel in May 2026. These increases are putting pressure on collagen extraction, drying, packaging, and transportation expenses. The World Bank also projected a 32% increase in global energy prices during 2026. Consequently, collagen producers may face higher operating costs and tighter profit margins, particularly those dependent on international raw material sourcing.

However, these disruptions are also encouraging manufacturers to diversify suppliers, strengthen regional sourcing, improve inventory management, and invest in efficient production technologies. Such measures are expected to support supply chain resilience despite geopolitical uncertainty.

Regional Insights

Dominating Region: Asia-Pacific – 41.23% Market Share, USD 3.2 Billion

Asia-Pacific held the leading position in the global collagen market in 2025, accounting for 41.23% of the market, valued at USD 3.2 billion. The region’s dominance is supported by strong demand for collagen-based dietary supplements, functional foods, pharmaceutical ingredients, and personal care products. China, Japan, and South Korea are important consumption and manufacturing markets, driven by increasing interest in beauty nutrition, healthy ageing, and preventive healthcare. The region also benefits from established food-processing and aquaculture industries. According to the Food and Agriculture Organization (FAO), Asia produced approximately 179 million tonnes of aquatic animals and algae in 2024, representing 76% of global production.

Marine-based collagen and nutraceutical applications are emerging as important growth opportunities across Asia-Pacific. Increasing demand for collagen powders, beauty supplements, functional beverages, and specialized nutritional products is encouraging manufacturers to expand their product portfolios. Japan and South Korea have established consumer markets for beauty and wellness products, while China offers opportunities through its expanding functional nutrition and food ingredient industries. According to FAO, Asian aquaculture produced approximately 130 million tonnes of aquatic animals and algae in 2024, providing a substantial raw material base for marine-derived ingredient development.

Collagen Market Regional Analysis

Key Regions and Countries Insights

North America
- US
- Canada
Europe
- Germany
- France
- The UK
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- South Korea
- India
- Australia
- Rest of APAC
Latin America
- Brazil
- Mexico
- Rest of Latin America
Middle East & Africa
- GCC
- South Africa
- Rest of MEA

Key Players Analysis

Rousselot, part of Darling Ingredients, is a major manufacturer of collagen and gelatin solutions for the food, nutraceutical, pharmaceutical, and biomedical industries. The company has more than 130 years of industry experience and operates 16 production facilities across 8 countries and 4 continents. Its portfolio includes more than 400 collagen and gelatin products, including Peptan and Nextida. Rousselot focuses on product innovation, advanced collagen peptides, and specialized ingredients for health and wellness applications.

GELITA AG is a Germany-based manufacturer specializing in collagen proteins, gelatin, and bioactive collagen peptides. Founded in 1875, the company has more than 150 years of industry experience, employs over 2,900 people, and operates more than 20 production sites worldwide. Its products serve the food, pharmaceutical, dietary supplement, cosmetics, and medical technology industries. GELITA continues to focus on research, production efficiency, and specialized collagen ingredients for applications such as joint health, skin nutrition, and pharmaceutical formulations.

Tessenderlo Group participates in the collagen industry through its PB Leiner business, which manufactures gelatin and collagen peptides for food, pharmaceutical, and health applications. In December 2025, Tessenderlo Group signed a definitive agreement with Darling Ingredients to combine PB Leiner and Rousselot into a new collagen-focused company. Under the proposed structure, Darling Ingredients would hold an 85% ownership stake, while Tessenderlo Group would hold 15%. The partnership aims to strengthen global manufacturing capabilities and expand collagen-based health, wellness, and nutrition products.

Top Key Players Outlook

Rousselot
GELITA AG
Tessenderlo Group
STERLING Biotech
Weishardt Holding SA
Juncà Gelatines SL
Symatese
Regenity
Collagen Solution LLC
ConnOils LLC
Advanced BioMatrix, Inc.
Other Key Players

Recent Developments

In FY2025, Zydus Lifesciences reported the formation of a 50:50 joint venture with Sterling Biotech following its acquisition of a 50% stake for INR 550 crore from Perfect Day Inc. The partnership also planned a specialized manufacturing facility for fermented animal-free proteins, although this development relates to alternative proteins rather than collagen production.
In May 2026, Weishardt Holding SA introduced Naticol UltraPeptide, an ultra-low molecular-weight marine collagen ingredient with an average molecular weight of 500 Daltons and approximately 45% di- and tripeptides. The ingredient was developed for use in powders, capsules, gummies, shots, and skincare formulations, with reported effective daily intake starting at 0.5 grams.

Report Scope

Report Features	Description
Market Value (2025)	USD 7.8 Bn
Forecast Revenue (2035)	USD 19.0 Bn
CAGR (2026-2035)	9.3%
Base Year for Estimation	2025
Historic Period	2020-2024
Forecast Period	2026-2035
Report Coverage	Revenue Forecast, Market Dynamics, Competitive Landscape, Recent Developments
Segments Covered	By Product (Gelatin, Hydrolyzed Collagen, Native Collagen, Synthetic Collagen, Other Product), By Source (Bovine, Porcine, Poultry, Marine, Other Source), By Application (Food & Beverages, Healthcare, Cosmetics, Other Application), By Disribution Channel (B2B, Distributors)
Regional Analysis	North America – US, Canada; Europe – Germany, France, The UK, Spain, Italy, Rest of Europe; Asia Pacific – China, Japan, South Korea, India, Australia, Singapore, Rest of APAC; Latin America – Brazil, Mexico, Rest of Latin America; Middle East & Africa – GCC, South Africa, Rest of MEA
Competitive Landscape	Rousselot, GELITA AG, Tessenderlo Group, STERLING Biotech, Weishardt Holding SA, Juncà Gelatines SL, Symatese, Regenity, Collagen Solution LLC, ConnOils LLC, Advanced BioMatrix, Inc., Other Key Players
Customization Scope	Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements.
Purchase Options	We have three licenses to opt for: Single User License, Multi-User License (Up to 5 Users), Corporate Use License (Unlimited User and Printable PDF)

Segments	Sub-segments
By Product	Gelatin Hydrolyzed Collagen Native Collagen Synthetic Collagen Other Product
By Source	Bovine Porcine Poultry Marine Other Source
By Application	Food & Beverages Healthcare Cosmetics Other Application
By Disribution Channel	B2B Distributors